Cargando…

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis

INTRODUCTION: Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1–3 months) comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bainey, Kevin R., Marquis-Gravel, Guillaume, MacDonald, Blair J., Bewick, David, Yan, Andrew, Turgeon, Ricky D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473507/
https://www.ncbi.nlm.nih.gov/pubmed/37656721
http://dx.doi.org/10.1371/journal.pone.0291061
_version_ 1785100288922746880
author Bainey, Kevin R.
Marquis-Gravel, Guillaume
MacDonald, Blair J.
Bewick, David
Yan, Andrew
Turgeon, Ricky D.
author_facet Bainey, Kevin R.
Marquis-Gravel, Guillaume
MacDonald, Blair J.
Bewick, David
Yan, Andrew
Turgeon, Ricky D.
author_sort Bainey, Kevin R.
collection PubMed
description INTRODUCTION: Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1–3 months) compared to standard DAPT (6–12 months) on bleeding and ischemic events in HBR PCI. METHODS: We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1–3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. RESULTS: From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84–1.23), all-cause death (RR 0.92, 95% CI 0.71–1.20) or stent thrombosis (RR 1.47, 95% CI 0.73–2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13–0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44–0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. CONCLUSIONS: In HBR PCI, DAPT for 1–3 months compared to 6–12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.
format Online
Article
Text
id pubmed-10473507
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-104735072023-09-02 Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis Bainey, Kevin R. Marquis-Gravel, Guillaume MacDonald, Blair J. Bewick, David Yan, Andrew Turgeon, Ricky D. PLoS One Research Article INTRODUCTION: Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1–3 months) compared to standard DAPT (6–12 months) on bleeding and ischemic events in HBR PCI. METHODS: We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1–3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. RESULTS: From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84–1.23), all-cause death (RR 0.92, 95% CI 0.71–1.20) or stent thrombosis (RR 1.47, 95% CI 0.73–2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13–0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44–0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. CONCLUSIONS: In HBR PCI, DAPT for 1–3 months compared to 6–12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI. Public Library of Science 2023-09-01 /pmc/articles/PMC10473507/ /pubmed/37656721 http://dx.doi.org/10.1371/journal.pone.0291061 Text en © 2023 Bainey et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bainey, Kevin R.
Marquis-Gravel, Guillaume
MacDonald, Blair J.
Bewick, David
Yan, Andrew
Turgeon, Ricky D.
Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title_full Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title_fullStr Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title_full_unstemmed Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title_short Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
title_sort short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473507/
https://www.ncbi.nlm.nih.gov/pubmed/37656721
http://dx.doi.org/10.1371/journal.pone.0291061
work_keys_str_mv AT baineykevinr shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis
AT marquisgravelguillaume shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis
AT macdonaldblairj shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis
AT bewickdavid shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis
AT yanandrew shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis
AT turgeonrickyd shortdualantiplatelettherapydurationafterpercutaneouscoronaryinterventioninhighbleedingriskpatientssystematicreviewandmetaanalysis